

Dear Author,

Here are the proofs of your article.

- You can submit your corrections **online**, via **e-mail** or by **fax**.
- For **online** submission please insert your corrections in the online correction form. Always indicate the line number to which the correction refers.
- You can also insert your corrections in the proof PDF and **email** the annotated PDF.
- For fax submission, please ensure that your corrections are clearly legible. Use a fine black pen and write the correction in the margin, not too close to the edge of the page.
- Remember to note the **journal title**, **article number**, and **your name** when sending your response via e-mail or fax.
- **Check** the metadata sheet to make sure that the header information, especially author names and the corresponding affiliations are correctly shown.
- **Check** the questions that may have arisen during copy editing and insert your answers/ corrections.
- **Check** that the text is complete and that all figures, tables and their legends are included. Also check the accuracy of special characters, equations, and electronic supplementary material if applicable. If necessary refer to the *Edited manuscript*.
- The publication of inaccurate data such as dosages and units can have serious consequences. Please take particular care that all such details are correct.
- Please **do not** make changes that involve only matters of style. We have generally introduced forms that follow the journal's style. Substantial changes in content, e.g., new results, corrected values, title and authorship are not allowed without the approval of the responsible editor. In such a case, please contact the Editorial Office and return his/her consent together with the proof.
- If we do not receive your corrections **within 48 hours**, we will send you a reminder.
- Your article will be published **Online First** approximately one week after receipt of your corrected proofs. This is the **official first publication** citable with the DOI. **Further changes are, therefore, not possible.**
- The **printed version** will follow in a forthcoming issue.

#### **Please note**

After online publication, subscribers (personal/institutional) to this journal will have access to the complete article via the DOI using the URL: [http://dx.doi.org/\[DOI\]](http://dx.doi.org/[DOI]).

If you would like to know when your article has been published online, take advantage of our free alert service. For registration and further information go to: <http://www.link.springer.com>.

Due to the electronic nature of the procedure, the manuscript and the original figures will only be returned to you on special request. When you return your corrections, please inform us if you would like to have these documents returned.

# Metadata of the article that will be visualized in OnlineFirst

---

ArticleTitle	Pollen allergy and health behavior: patients trivializing their disease	
--------------	---	--

---

Article Sub-Title		
-------------------	--	--

---

Article CopyRight	Springer Nature B.V. (This will be the copyright line in the final PDF)	
-------------------	--	--

---

Journal Name	Aerobiologia	
--------------	--------------	--

---

Corresponding Author	Family Name	<b>Damialis</b>
	Particle	
	Given Name	<b>Athanasios</b>
	Suffix	
	Division	Chair and Institute of Environmental Medicine, UNIKA-T, Research Center for Environmental Health
	Organization	Technical University of Munich and Helmholtz Zentrum München
	Address	Augsburg, Germany
	Phone	+49 (0)821 - 598 6414
	Fax	
	Email	thanos.damialis@tum.de
	URL	
	ORCID	<a href="http://orcid.org/0000-0003-2917-5667">http://orcid.org/0000-0003-2917-5667</a>

---

Author	Family Name	<b>Muzalyova</b>
	Particle	
	Given Name	<b>Anna</b>
	Suffix	
	Division	Chair of Health Care Operations/Health Information Management, UNIKA-T
	Organization	University of Augsburg
	Address	Universitätsstraße 16, 86159, Augsburg, Germany
	Phone	
	Fax	
	Email	anna.muzalyova@unikat.uni-augsburg.de
	URL	
	ORCID	

---

Author	Family Name	<b>Brunner</b>
	Particle	
	Given Name	<b>Jens O.</b>
	Suffix	
	Division	Chair of Health Care Operations/Health Information Management, UNIKA-T
	Organization	University of Augsburg
	Address	Universitätsstraße 16, 86159, Augsburg, Germany
	Phone	
	Fax	

Email jens.brunner@unikat.uni-augsburg.de  
URL  
ORCID

---

Author	Family Name	<b>Traidl-Hoffmann</b>
	Particle	
	Given Name	<b>Claudia</b>
	Suffix	
	Division	Chair and Institute of Environmental Medicine, UNIKA-T, Research Center for Environmental Health
	Organization	Technical University of Munich and Helmholtz Zentrum München
	Address	Augsburg, Germany
	Division	
	Organization	CK CARE Christine Kühne Center for Allergy Research and Education
	Address	Davos, Switzerland
	Division	Outpatient Clinic for Environmental Medicine
	Organization	Klinikum Augsburg
	Address	Augsburg, Germany
	Phone	
	Fax	
	Email	claudia.traidl-hoffmann@tum.de
	URL	
	ORCID	

---

---

Schedule	Received	13 July 2018
	Revised	
	Accepted	9 January 2019

---

**Abstract** Allergies are increasing in prevalence worldwide, with socioeconomic impacts and effects on quality of life. The aim of this study was to explore the health behavior and the utilization of different treatment options via questionnaires and to investigate for relationships of the above with socioeconomic factors. This cross-sectional survey was carried out among pollen allergic subjects in 2016, using questionnaires. A total of 679 Allergics participated in the study (61.2% females). Their average age was  $26.8 \pm 8.8$  years. Their symptom severity was  $6.1 \pm 1.9$ , measured on a 10-step scale and symptoms lasted for  $9.0 \pm 6.8$  weeks during pollen season. Of all allergics, 9.1% were not aware of the causative agent of their allergy and 17.4% had never undergone allergy testing. Symptoms, especially in females, had strong impact on social life, everyday routines and sleep quality. Almost half of the participants treated their allergy without medical supervision, while only 32.3% sought medical support. Nevertheless, three quarters reported self-management of their allergies with oral antihistamines. Compared to males, females sought significantly more medical support, medications and allergen avoidance strategies. Knowledge about allergy increased the likelihood of treatment under supervision of a medical expert than no treatment, as well as symptom severity and interaction between female gender and symptom severity. The attitude of not considering allergy as a serious disease significantly reduced the likelihood of undergoing specific immunotherapy. This survey not only highlights the negative impact of pollen allergies on everyday life of allergics, but also that allergies are often neglected and untreated because of their trivialization by allergic subjects themselves.

---

**Keywords (separated by '-')** Allergy impairment - Allergy management - Allergy treatment - Health behavior - Pollen allergy

---

**Footnote Information**

---

2 **Pollen allergy and health behavior: patients trivializing their**  
3 **disease**

4 **Anna Muzalyova · Jens O. Brunner · Claudia Traidl-Hoffmann ·**  
5 **Athanasios Damialis** 

6 Received: 13 July 2018 / Accepted: 9 January 2019  
7 © Springer Nature B.V. 2019

8 **Abstract** Allergies are increasing in prevalence  
9 worldwide, with socioeconomic impacts and effects  
10 on quality of life. The aim of this study was to explore  
11 the health behavior and the utilization of different  
12 treatment options via questionnaires and to investigate  
13 for relationships of the above with socioeconomic  
14 factors. This cross-sectional survey was carried out  
15 among pollen allergic subjects in 2016, using ques-  
16 tionnaires. A total of 679 Allergics participated in the  
17 study (61.2% females). Their average age was  
18  $26.8 \pm 8.8$  years. Their symptom severity was  
19  $6.1 \pm 1.9$ , measured on a 10-step scale and symptoms  
20 lasted for  $9.0 \pm 6.8$  weeks during pollen season. Of  
21 all allergics, 9.1% were not aware of the causative  
22 agent of their allergy and 17.4% had never undergone  
23 **AQ1** allergy testing. Symptoms, especially in females, had  
24 strong impact on social life, everyday routines and

sleep quality. Almost half of the participants treated 25  
their allergy without medical supervision, while only 26  
32.3% sought medical support. Nevertheless, three 27  
quarters reported self-management of their allergies 28  
with oral antihistamines. Compared to males, females 29  
sought significantly more medical support, medica- 30  
tions and allergen avoidance strategies. Knowledge 31  
about allergy increased the likelihood of treatment 32  
under supervision of a medical expert than no 33  
treatment, as well as symptom severity and interaction 34  
between female gender and symptom severity. The 35  
attitude of not considering allergy as a serious disease 36  
significantly reduced the likelihood of undergoing 37  
specific immunotherapy. This survey not only high- 38  
lights the negative impact of pollen allergies on 39  
everyday life of allergics, but also that allergies are 40

A1 A. Muzalyova · J. O. Brunner  
A2 Chair of Health Care Operations/Health Information  
A3 Management, UNIKA-T, University of Augsburg,  
A4 Universitätsstraße 16, 86159 Augsburg, Germany  
A5 e-mail: anna.muzalyova@unikat.uni-augsburg.de  
A6 J. O. Brunner  
A7 e-mail: jens.brunner@unikat.uni-augsburg.de

A8 C. Traidl-Hoffmann · A. Damialis (✉)  
A9 Chair and Institute of Environmental Medicine, UNIKA-  
A10 T, Research Center for Environmental Health, Technical  
A11 University of Munich and Helmholtz Zentrum München,  
A12 Augsburg, Germany  
A13 e-mail: claudia.traidl-hoffmann@tum.de

A14 A. Damialis  
A15 e-mail: thanos.damialis@tum.de

A16 C. Traidl-Hoffmann  
A17 CK CARE Christine Kühne Center for Allergy Research  
A18 and Education, Davos, Switzerland

A19 C. Traidl-Hoffmann  
A20 Outpatient Clinic for Environmental Medicine, Klinikum  
A21 Augsburg, Augsburg, Germany

41 often neglected and untreated because of their trivi-  
42 alization by allergic subjects themselves.

43 **Keywords** Allergy impairment · Allergy  
44 management · Allergy treatment · Health behavior ·  
45 Pollen allergy

## 46 1 Background

47 Allergic diseases such as allergic rhinitis (AR) and  
48 allergic asthma have been increasing in industrialized  
49 countries over the last decades (Ring et al. 2012;  
50 Traidl-Hoffmann 2017). The current prevalence rates  
51 of allergic rhinitis stagnate on a high level ranging  
52 from 15 to 25% worldwide (Passali et al. 2018).

53 Allergy can reduce health-related quality of life  
54 because of the profound physical and psychosocial  
55 complications and for sure because of the allergy  
56 itself. Many studies have shown that allergic symp-  
57 toms impair the usual performance of daily activities,  
58 quality of sleep, work productivity (Blais et al. 2018;  
59 Jernelöv et al. 2013; Meltzer 2016; Muñoz-Cano et al.  
60 2018; Schoenwetter et al. 2004; Vuurman et al. 2014)  
61 and also have an impact on psychological well-being  
62 and perceived quality of life (Devillier et al. 2016b;  
63 Haanpää et al. 2018; Leynaert et al. 2000; Meltzer  
64 2001). Furthermore, allergies are associated with  
65 embarrassment by allergic symptoms and being trou-  
66 bled by frustration and missing work or class time, the  
67 so-called absenteeism (Goetzel et al. 2004). Allergy  
68 affects the ability to learn, mainly as the result of  
69 frequent sleep disturbances, which, in turn, are  
70 responsible for daytime sleepiness, fatigue, headache  
71 or cognitive impairment (Jáuregui et al. 2009). But  
72 also the accompanying allergy manifestations, like  
73 allergic conjunctivitis, can lower the performance of  
74 daily activities and reduce workplace productivity,  
75 because of pruritic or watery eyes and consequently  
76 blurred sight (Klossek et al. 2012). Also, atopic  
77 dermatitis and associated skin itching have a substan-  
78 tial impact on sleep quality of concerned people,  
79 causing sleep deprivation and consequent daily tired-  
80 ness and mood changes (Simpson et al. 2016).  
81 Because atopic dermatitis starts even as a childhood  
82 disease, parents might just as well negatively affected  
83 (Carroll et al. 2005). Finally, asthma episodes, being  
84 the most severe manifestation of atopic disorders, are

85 accompanied by airway obstruction and hinder asth-  
86 matics in everyday activities at school and work, and  
87 worsen their social life. An asthma attack may cause  
88 an urgent need for the allergic person to be immedi-  
89 ately treated, even hospitalized (Asher and Pearce  
90 2014).

91 Apart from direct health effects, allergic disorders  
92 and asthma are considered responsible for high  
93 socioeconomic impacts due to presenteeism and  
94 absenteeism. Presenteeism is defined as the loss of  
95 productivity because of the presence of symptoms of a  
96 disease (Blais 2007). Vandenplas et al. (2018)  
97 reviewed the productivity burden of allergic rhinitis  
98 and found a substantial effect of this chronic condition  
99 on absenteeism and presenteeism. The overall eco-  
100 nomic impact of allergies accounted for 35.9% of  
101 impaired at-work productivity and 3.6% missed work  
102 time (Vandenplas et al. 2018). Allergies are the second  
103 most frequent contributor to the total costs of health-  
104 related absenteeism and presenteeism in Germany  
105 (Badura et al. 2010). The rate of absenteeism among  
106 employed allergic subjects in Germany accounts to  
107 3 days per year. The rate of productivity loss due to  
108 presenteeism ranges between 10 and 20% (Zuberbier  
109 et al. 2014). Moreover, the majority of economic  
110 burden of pollen allergies is to a larger extent due to  
111 high levels of absenteeism and presenteeism in pollen  
112 allergic subjects, rather than treatment cost itself  
113 (Linneberg et al. 2016).

114 Proper and timely treatment of allergy can lead to  
115 relief of symptoms and consequently minimizes the  
116 negative socioeconomic burden of the disease. Allergy  
117 is a chronic disease, hence requiring a long-time  
118 therapy. There are three main possibilities for treat-  
119 ment of allergic disorders: allergen avoidance, symp-  
120 tomatic pharmacotherapy and specific immunotherapy  
121 (May and Dolen 2017). Allergen avoidance may  
122 significantly reduce the severity of symptoms, but it is  
123 seldom sufficient alone for controlling allergic symp-  
124 toms, as it is very difficult to completely avoid allergen  
125 exposure. Oral antihistamines remain the most effec-  
126 tive method against the major symptoms of allergy.  
127 However, they are not consistently effective against all  
128 kinds of symptoms. So, additional use of topical  
129 medication might still be needed. Furthermore, all  
130 available drugs offer only temporary relief and, hence,  
131 specific immunotherapy is the only curative treatment  
132 for allergic disorders with relevant socioeconomic  
133 implication (Meadows et al. 2013).

134 Many people with pollen allergy do not manage  
 135 their disease under medical supervision, but only by  
 136 use of over-the-counter antihistamines, which are  
 137 selected based on the patient's own perception of  
 138 medication effectiveness (Tan et al. 2017). Due to this  
 139 fact, many AR treatments are taken only occasionally  
 140 and when seeking immediate relief of more severe  
 141 symptoms, although regular intake is normally rec-  
 142 ommended in such cases. Non-adherence to AR  
 143 medical treatment has not been thoroughly investi-  
 144 gated, probably as a result of AR trivialization,  
 145 compared to other allergic diseases (Bender 2015).  
 146 Effective allergy management largely depends on the  
 147 selection of and adherence to the most appropriate  
 148 treatment and consequently on the health behavior of  
 149 the allergic patient. To elucidate this, the aim of this  
 150 study was to analyze and evaluate the health-related  
 151 behavior of allergic subjects, including awareness and  
 152 utilization of different treatment options as well as  
 153 adherence to chosen treatment methods. To achieve  
 154 this, potential behavioral patterns were examined for  
 155 relationships with demographic factors, allergy char-  
 156 acteristics and adopted attitudes toward the patient's  
 157 own disease. Such patterns in allergy treatment  
 158 behavior and adherence to management methods can  
 159 contribute, in the longer-term, to the development of  
 160 operational health information services and most  
 161 efficient health care delivery.

## 162 2 Materials and methods

163 This cross-sectional, explorative survey was con-  
 164 ducted between June 02 and July 12, 2016. We  
 165 defined our target group to be pollen allergic subjects.  
 166 The inclusion criteria were defined as follows: the  
 167 participants had to have exhibited allergic reactions  
 168 during the year of the study or the year before and not  
 169 being additionally sensitized against dust mites. All  
 170 previous information was self-reported. The study  
 171 participants not fulfilling the inclusion criteria were  
 172 excluded from the data analysis. Questionnaires were  
 173 disseminated by an online survey tool among all test  
 174 persons, recruited in the course of a first, preliminary,  
 175 study, conducted in October 2015, aiming to evaluate  
 176 the benefit of the application-based pollen informa-  
 177 tion. In addition, we invited all matriculated students  
 178 of the University of Augsburg, along with the univer-  
 179 sity's personnel, scientific or not. We received 698

180 filled out questionnaires. Of them, 19 were excluded  
 181 since they did not fulfill the inclusion criteria.  
 182 Consequently, 679 datasets were included in the data  
 183 analysis.

184 The questionnaire was designed aiming to collect  
 185 information on the health behavior of allergic persons,  
 186 and, in this respect, it was divided into seven thematic  
 187 areas. In the first part, demographic data like gender  
 188 and age and the highest acquired educational degree  
 189 were requested. Items of the next sector inquired  
 190 general information about the perception of the allergy  
 191 and its occurrence, like agents causing allergic reac-  
 192 tion, severity of symptoms (10-step scale) and their  
 193 persistence within the pollen season and also the  
 194 duration of the allergic disease in general. Note that for  
 195 polysensitized participants we asked to indicate only  
 196 the strongest allergy. In the third part, participants  
 197 were asked to provide information on several allergen  
 198 avoidance strategies that they are aware of and that  
 199 they use during the pollen season. One of the core parts  
 200 of the questionnaire represented the items investigat-  
 201 ing the treatment and management of the allergic  
 202 disease by asking for medical assistance, as seeking  
 203 medical support for new prescription, medication or  
 204 advice, or conducting specific immunotherapy. In the  
 205 fifth part of the questionnaire, we collected the  
 206 information about the use of pollen information  
 207 services and also the study participants were asked  
 208 to evaluate their state of knowledge about allergy on a  
 209 10-step scale. In the sixth part, the respondents were  
 210 asked to recall how affected they had been by their  
 211 allergic symptoms and which kinds of limitations they  
 212 had experienced while being symptomatic. To quan-  
 213 tify this, they were called to estimate their impairment  
 214 on a 4-step scale (1 = never, 2 = seldom, 3 = some-  
 215 times, 4 = often). Moreover, they were asked to  
 216 approximate the loss of productivity by recording the  
 217 estimated performance on days with and without the  
 218 presence of allergic symptoms. The difference  
 219 between those two instances was evaluated. The  
 220 seventh part was developed in order to gather infor-  
 221 mation on personal attitude toward allergy and con-  
 222 sisted of 12 5-step-scaled items (1 = totally disagree,  
 223 2 = rather disagree, 3 = neutral, 4 = rather agree,  
 224 5 = totally agree). This category includes such atti-  
 225 tudes like considering the own allergy as a chronic and  
 226 serious disease or a challenge someone wants to  
 227 master, or, on the other hand, attitudes of the allergic

228 subjects as if they were not allergic or as if they had the  
229 allergy well under control.

### 230 3 Data analysis

231 All included questionnaires ( $n = 679$ ) were analyzed  
232 using SPSS 24 (Statistical Package for the Social  
233 Sciences; SPSS Inc., Chicago, IL, USA). Data were  
234 statistically described in terms of mean or median and  
235 standard deviation (SD) for interval-scaled and ordi-  
236 nal-scaled values and frequencies (number of cases as  
237 absolute numbers or percentages) when appropriate,  
238 for nominal scaled values. Correlation analysis  
239 between two and more variables was performed by  
240 applying Spearman's rho and Kendall's tau coeffi-  
241 cients, depending on the scale of measurement and due  
242 to the missing normal distribution of the data.  
243 Comparison of the mean values between two unpaired  
244 groups was done using Mann-Whitney  $U$  test and  
245 Wilcoxon test for paired samples. Comparison  
246 between more than two groups was conducted by  
247 Kruskal-Wallis test. For comparing categorical data,  
248 Chi-square ( $\chi^2$ ) test was performed. (Multinomial)  
249 logistic regression was applied to investigate the  
250 relationship between categorically scaled dependent  
251 variables and relevant independent variables. Eighteen  
252 independent variables were included in the primary  
253 model considering main effects as well as all 2-way  
254 interactions. Backward elimination was used for  
255 variable selection. Statistical significance was consid-  
256 ered at the 0.95 level ( $p < 0.05$ ). As the present survey  
257 was explorative in nature and presupposed testing  
258 many hypotheses, we had to correct our results by  
259 multiple testing in order to check for false positives.  
260 Hence, all  $p$  values were adjusted using the Ben-  
261 jamini-Yekutieli step-up procedure.

### 262 4 Results

#### 263 4.1 Participants' characteristics

264 Females constituted 61.2% ( $n = 414$ ) of the total  
265 number of the participants. The mean age of the  
266 participants was  $26.8 \pm 8.8$  years. In addition, the  
267 majority of 96.2% ( $n = 650$ ) reached university level  
268 of education. The allergic participants exhibited  
269 symptoms for  $12.7 \pm 9.3$  years on average, and the

symptom severity was  $6.1 \pm 1.9$ , based on a 10-step  
270 scale. Allergic symptoms on average commenced at  
271 the age of  $14.2 \pm 7.5$ . Within the pollen season,  
272 participants showed allergic symptoms for approxi-  
273 mately  $9.0 \pm 6.8$  weeks.  
274

275 The allergologically relevant pollen types were  
276 grasses, followed by birch and hazel, with a contribu-  
277 tion to the total of 78.3% ( $n = 529$ ), 51.8% ( $n = 350$ )  
278 and 37.6% ( $n = 254$ ), respectively. Approximately  
279 20.0% ( $n = 132$ ) of the participants were allergic  
280 against only one pollen type, and 22.6% ( $n = 153$ )  
281 against two pollen types. A relatively high proportion  
282 of allergic subjects (9.1% of the total) did not know  
283 their causative agent and 17.4% ( $n = 122$ ) of the  
284 sample had never undergone allergy testing. The part  
285 of the cohort not aware of what pollen type they were  
286 allergic to, usually had not acquired confirmed allergy  
287 diagnosis [ $\chi^2(1) = 142.2, p < 0.01$ ]. All previous  
288 information was self-reported by participants.

289 Table 1 displays the correlation coefficients of four  
290 allergy characteristics and shows that nearly all  
291 inquired allergy features were related to each other.  
292 The strongest correlations were observed between  
293 either symptom severity and symptom duration, or  
294 symptom severity and multiple responses to different  
295 pollen types.

296 Regarding gender-specific differences in allergy  
297 characteristics (Table 2), women exhibited signifi-  
298 cantly higher values in cross-reactive responses and  
299 duration of symptoms. However, perceived symptom  
300 severity and years of disease did not significantly  
301 differ between genders [ $U(412, 256) = 48,246,$   
302  $p = 0.09$ ]. For further data analysis, we assumed that  
303 symptoms were of the same severity in both males and  
304 females.

#### 305 4.2 Avoidance strategies

306 In general, participants were sufficiently informed  
307 concerning possible avoidance strategies, like "keep  
308 windows closed," "do not stay outside for long time"  
309 and "shower daily before sleep". On average, they  
310 were aware of  $6.7 \pm 2.1$  of the 10 mentioned strate-  
311 gies. Nevertheless, they used only half of them to  
312 avoid allergen exposure ( $3.4 \pm 2.0$ ), which makes a  
313 significant difference in comparison with the known  
314 strategies (Wilcoxon,  $Z = 21.48, p < 0.01$ ).

315 Analysis of dependencies between known and used  
316 strategies and allergy characteristics (Table 3) showed

**Table 1** Spearman-correlation matrix of four allergy characteristics

	(1)	(2)	(3)	(4)
(1) Responses to multiple pollen types	1			
(2) Symptom severity	0.37**	1		
(3) Years of disease	0.26**	0.09	1	
(4) Duration of symptoms	0.23*	0.41**	0.06	1

\*Significance level  $p < 0.05$ , \*\*significance level  $p < 0.01$

**Table 2** Self-reported allergy characteristics by gender

	Males		Females		<i>p</i> value
	Mean $\pm$ SD	Median	Mean $\pm$ SD	Median	
Responses to multiple pollen types	2.3 $\pm$ 1.9	2.0	2.7 $\pm$ 2.0	2.0	$p < 0.01$
Symptom severity (10-step scale)	5.9 $\pm$ 1.8	6.0	6.2 $\pm$ 1.9	6.0	$p = 0.09$ (n.s.)
Disease duration (in years)	13.6 $\pm$ 0.4	11.5	12.2 $\pm$ 0.5	10.0	$p = 0.02$ (n.s.) <sup>†</sup>
Duration of symptoms (in weeks within the pollen season)	7.7 $\pm$ 5.4	6.0	9.8 $\pm$ 7.5	8.0	$p < 0.01$

n.s. Not significant, <sup>†</sup> not significant due to multiple testing

**Table 3** Spearman correlations between allergy characteristics and avoidance strategies

	Responses to multiple pollen types	Symptom severity	Years of disease	Duration of symptoms
Strategies known to the respondent	0.25**	0.12*	0.20**	0.14**
Strategies used by the respondent	0.25**	0.26**	0.12*	0.15**

\*Significance level  $p < 0.05$ , \*\*significance level  $p < 0.01$

317 that used avoidance strategies correlated stronger with  
318 the severity of symptoms, whereas the known strate-  
319 gies correlated more with the years of disease.  
320 Furthermore, female subjects followed approximately  
321  $3.6 \pm 2.0$  avoidance strategies and men fewer,  
322  $3.0 \pm 1.9$ , which highlights a significant difference  
323 between genders [ $U(414, 254) = 43,317.5, p < 0.01$ ].


### 324 4.3 Allergy treatment

325 Almost half of the participants suffering from hay  
326 fever ( $n = 318$ ) treated themselves without medical  
327 supervision and 20.7% ( $n = 140$ ) did not treat their

328 allergy at all (Fig. 1). Only one-third ( $n = 218$ ) was  
329 treated by a medical doctor. Compared to women, men  
330 were less treated by a doctor [ $\chi^2(1) = 11.79,$   
331  $p < 0.01$ ].

332 The main reasons for those respondents treating  
333 their pollen allergy without any medical supervision  
334 were low severity of occurring symptoms (42.8%),  
335 low treatment expectations (16.0%) and lack of time  
336 (15.6%). The cohort of not treated allergic subjects  
337 stated the same two main reasons for no treatment,  
338 namely low severity of symptoms and low treatment  
339 expectations with a frequency of 44.2% and 15.6%,  
340 respectively. Additional causes of non-treatment were



**Fig. 1** Self-reported pollen allergy treatment type

341 lack of information on the therapy possibilities  
 342 (13.9%) and lack of curative therapy methods  
 343 (13.4%).


344 Despite the low rate of respondents treated by a  
 345 doctor, still three quarters of the total number of  
 346 respondents ( $n = 503$ ) were taking medication against  
 347 allergic symptoms. The frequency and distribution of  
 348 different medications among hay fever sufferers are  
 349 shown in Fig. 2. About 90.0% ( $n = 442$ ) of partici-  
 350 pants treated their pollen allergy with oral antihis-  
 351 tamines, whereas throat spray seemed to be the least  
 352 popular and was used only in 9.0% ( $n = 39$ ) of cases.  
 353 The frequency of anti-allergic medication use varied  
 354 from every day to maximal 3 days per week. The  
 355 majority of the participants that did not take medica-  
 356 tion regularly preferred to take it only on demand. The  
 357 amount of different medicines used by allergic sub-  
 358 jects on average accounted to  $2.1 \pm 0.9$ , with women  
 359 using on average more medication than men [ $U$  (175,  
 360 323) = 19,968,  $p < 0.01$ ]. Among the participants that  
 361 treated their allergy under medical supervision, 86.7%  
 362 ( $n = 189$ ) were taking anti-allergic medication, with  
 363 almost half of them ( $n = 89$ ) taking it daily. A similar  
 364 percentage (88.7%,  $n = 282$ ) of pollen allergic  
 365 patients that treated their disease without medical  
 366 supervision were anyway receiving this kind of  
 367 medication, with only one-third of them ( $n = 91$ )  
 368 taking it daily. Regarding the third category of allergic  
 369 individuals in our survey, those claiming not treating  
 370 their allergy at all, about one-fifth ( $n = 32$ ) still

371 responded that they were taking medication against  
 372 allergic symptoms.

373 The oral antihistamines were taken on average for  
 374  $8.5 \pm 7.4$  weeks within the pollen season, which  
 375 almost matches the mean persistence of allergic  
 376 symptoms in hay fever sufferers. Specific  
 377 immunotherapy was received by only 35.0%  
 378 ( $n = 237$ ) of the participants. Allergic subjects that  
 379 perceived their symptoms as more severe were more  
 380 likely to undergo specific immunotherapy [ $U$  (232,  
 381 442) = 38,145,  $p < 0.01$ ]. Of those following  
 382 immunotherapy, 53.4% ( $n = 124$ ) reported reduction  
 383 of their symptoms and a positive overall effect on their  
 384 well-being. Nonetheless, 40.6% of the respondents  
 385 ( $n = 94$ ) did not notice any difference and 6.0%  
 386 ( $n = 14$ ) claimed that their symptoms even worsened.

387 A relatively big group of 43.5% ( $n = 294$ ) of the  
 388 hay fever sufferers in the survey reported that they did  
 389 not usually seek medical attention during the pollen  
 390 season. Another 33.7% ( $n = 228$ ) attended the doctor  
 391 when only being symptomatic, but this was rarely. The  
 392 most common reasons for visiting a medical doctor  
 393 were the prescription of new medication (26.1%),  
 394 seeking for alternative treatment methods (26.7%) and  
 395 general advice for hay fever management (26.5%).  
 396 Females were more likely to decide to be supervised  
 397 by a medical expert and consequently visited a doctor  
 398 more often than males [ $U$  (254, 414) = 42,922,  
 399  $p < 0.01$ ].

**Fig. 2** Frequency of the utilization of different kinds of anti-allergic medication



#### 400 4.4 Awareness and perception of allergy

401 Overall awareness of hay fever general knowledge  
 402 was  $5.9 \pm 2.0$  on a 10-step scale and correlates with  
 403 known strategies of allergy avoidance ( $r = 0.39$ ,  
 404  $p < 0.01$ ). At the same time, 66.7% ( $n = 451$ ) of  
 405 respondents stated that they were looking for addi-  
 406 tional information about hay fever. A comparably big  
 407 proportion of respondents ( $n = 470$ ) indicates that  
 408 they were seeking advices on pollen allergy and its  
 409 management and 59.3% ( $n = 401$ ) of respondents  
 410 tended to exchange their knowledge regarding hay  
 411 fever with other persons concerned.

412 About 70.0% ( $n = 471$ ) of the survey participants  
 413 did not make use of any pollen information services.  
 414 The biggest part of those, namely 40.5% ( $n = 243$ ),  
 415 claimed not to be interested in this kind of services  
 416 because they perceived their allergy symptoms as  
 417 tolerable whatsoever. Another 32.5% ( $n = 195$ )  
 418 reported not to know how to use pollen forecasting  
 419 for their own benefit. The rest and smallest proportion,  
 420 either was not aware of such an information service or  
 421 considered the relevant pollen season predictions as  
 422 not reliable, with 15.0% ( $n = 90$ ) and 12.0% ( $n = 72$ ),  
 423 respectively. Among those who regularly used pollen  
 424 information services (30.0%,  $n = 205$ ), almost half  
 425 (52.0%,  $n = 160$ ) needed this information about future  
 426 airborne pollen concentrations so as to prepare men-  
 427 tally for the next day. The rest used this information to

adjust their medication (26.6%,  $n = 82$ ) or to plan their  
 daily activities (21.4%,  $n = 66$ ).

Frequencies of adopted attitudes of survey partic-  
 ipants toward pollen allergy are presented in Fig. 3.  
 The majority of the survey respondents seemed to  
 have accepted their allergies as part of their life,  
 having learnt to live with them or believing that they  
 manage their disease satisfactorily. On the other hand,  
 a relatively high proportion (about one-third) tended to  
 trivialize their condition by stating that allergy is not a  
 serious disease or even did not acknowledge that  
 allergy is a chronic disease.

AQ2 139

#### 4.5 Social life implications

The frequency of occurring social life implications  
 while being symptomatic can be seen in Table 4.  
 Significant differences in social life implications were  
 observed among men and women: allergy seemed to  
 have a more pronounced negative effect on women's  
 social life, manifested as social life limitations  
 $[U(253, 413) = 43,113.5, p < 0.01]$ , daily routine  
 limitations  $[U(254, 411) = 42,204, p < 0.01]$  and as  
 bad night sleep  $[U(254, 413) = 43,285, p < 0.01]$ .  
 Moreover, women experienced a significantly sharper  
 decline in work productivity than men  $[U(254,$   
 $414) = 41,555, p < 0.01]$  accounting for an average  
 of  $2.7 \pm 1.8$  in females and  $2.2 \pm 1.6$  in males on a  
 10-step scale. In general, 92.3% ( $n = 626$ ) of allergic  
 participants stated that they exhibited at least

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452


453

454

455



**Fig. 3** Adopted attitudes toward pollen allergy (% of survey participants)



**Table 4** Self-reported frequency (%) of social life implications by gender

	Never	Seldom	Sometimes	Often
Missing meetings with friends				
Females	60.5	27.4	11.0	1.0
Males	70.5	21.0	7.9	0.4
Limitation in social life				
Females	25.9	38.0	30.5	5.6
Males	39.1	37.9	17.4	5.5
Limitation in daily routines				
Females	8.8	28.5	44.3	18.5
Males	16.9	37.0	33.9	12.2
Sleep disturbance				
Females	17.7	31.2	33.4	17.1
Males	28.0	34.6	26.6	10.1

occasionally reduced productivity while being symptomatic.

There is a statistically significant relationship between all questioned implications and symptom severity, with the strongest correlation being with impairment of everyday activities (Kendall's tau,  $\tau = 0.40$ ,  $p < 0.01$ ). The mean loss of productivity while being symptomatic amounts to  $2.4 \pm 1.7$  points on a 10-step scale, which corresponds to a significant fall of productivity because of pollen exposure (Wilcoxon,  $Z = -21.49$ ,  $p < 0.01$ ). Loss of productivity also significantly correlated with symptom severity ( $r = 0.40$ ,  $p < 0.01$ ).

#### 4.6 Factors influencing allergy treatment

Differences between allergy management options that depend on external factors are presented in Table 5. It seems that gender alone did not significantly influence the way the allergic disease was managed, that is whether under medical supervision or without. Nonetheless, the interaction effect of gender and allergy severity affected females' decision to be supervised by a medical expert. As the symptom severity rose, females exhibited increased chance to seek medical attention by 53.0%, than to not treat their condition at all. Other factors positively influencing the preference of the treatment by a medical expert over no treatment at all were knowledge about allergy as well as severity of perceived symptoms, with knowledge exhibiting an even stronger effect than severity of the illness.

Particularly regarding specific immunotherapy, females were less keen on using it as an allergy management option (Table 6). Nonetheless, this pattern changed when their symptoms increased in severity and then they were more likely than men to treat their allergies using specific immunotherapy. Interestingly, this interaction between female gender and allergy severity increased the likelihood of undergoing the curative treatment by 39.0%. Moreover, the likelihood for using this method was higher when an allergic exhibited symptoms for more years or if they presented cross-reactive allergies. Whenever

**Table 5** Logistic regression of factors influencing the choice of the treatment type

	<i>B</i>	95% CI for odds ratio		
		Lower	Odds ratio	Upper
<i>Treatment by a doctor versus no treatment</i>				
Intercept	- 4.40**			
Gender (female)	- 2.00	0.02	0.15	0.82
Knowledge about allergy	0.48**	1.40	1.61	1.84
Symptom severity	0.20*	1.11	1.37	1.70
[Gender (female)] × [symptom severity]	0.42*	1.13	1.53	2.06
<i>Treatment on their own versus no treatment</i>				
Intercept	- 1.93**			
Gender (female)	- 0.75	0.12	0.47	1.88
Knowledge about allergy	0.30**	1.20	1.35	1.52
Symptom severity	0.19	1.01	1.20	1.44
[Gender (female)] × [symptom severity]	0.20	0.96	1.23	1.57

\*Significance level  $p < 0.05$ , \*\*significance level  $p < 0.01$   
 $R^2 = 0.23$  (Cox and Snell).  
 Model  $\chi^2$  (10) 176.60,  
 $p < 0.01$

**Table 6** Logistic regression of factors influencing the utilization of specific immunotherapy

	<i>B</i>	95% CI for odds ratio		
		Lower	Odds ratio	Upper
<i>Yes versus no</i>				
Constant	- 2.38**			
Gender (female)	- 4.07**	0.01	0.02	0.11
Years suffering from hay fever	0.12*	1.05	1.14	1.21
Cross-reactive responses	0.23**	1.13	1.28	1.39
Hay fever is not a serious illness	- 0.42**	0.51	0.66	0.85
[Gender (females)] × [symptom severity]	0.32**	1.11	1.38	1.73

\*Significance level  $p < 0.05$ , \*\*significance level  $p < 0.01$   
 $R^2 = 0.19$  (Cox and Snell).  
 Model  $\chi^2$  (10) 134.28,  
 $p < 0.01$

498 allergic subjects tended to trivialize their disease, they  
 499 did not consider undergoing immunotherapy.

500 Moreover, allergic subjects tended to seek for  
 501 medical assistance more often, either whenever they  
 502 had an increased allergy burden (i.e., reduced produc-  
 503 tivity) or when they were more self-aware and  
 504 knowledgeable regarding their disease (Table 7).  
 505 When they seemed to trivialize their condition, they  
 506 were less keen on asking for medical support and it  
 507 seemed to make no difference if they tried to ignore  
 508 their disease.

## 509 5 Discussion

510 The present cross-sectional, explorative study pro-  
 511 vides relevant information on the distribution of  
 512 allergic characteristics among pollen allergy sufferers  
 513 in Augsburg including information on their health

514 behavior and utilization of different treatment options. 514  
 515 With the present study, it is confirmed that pollen 515  
 516 allergies remain a serious health problem with a 516  
 517 profound effect on the health-related quality of 517  
 518 everyday life of allergic individuals, with negative 518  
 519 implications in social life, everyday activities but also 519  
 520 work productivity. Nonetheless, it was found that 520  
 521 approximately half of the participants surprisingly and 521  
 522 persistently preferred to treat their allergies without 522  
 523 medical supervision and almost one-third completely 523  
 524 dispensed with the treatment. Interestingly, though, 524  
 525 this effect seemed to differ between genders, as males 525  
 526 tended to trivialize their disease, to ignore their 526  
 527 symptoms and not to seek medical advice or treatment. 527

528 When considering these survey results, it must be 528  
 529 noted that participation in this study was on a 529  
 530 voluntary basis and that the survey was distributed to 530  
 531 all students and personnel of the University of 531  
 532 Augsburg via an online tool. It is acknowledged that 532

**Table 7** Logistic regression of factors influencing the frequency of received medical help

	B	95% CI for odds ratio		
		Lower	Odds ratio	Upper
<i>Never versus seldom</i>				
Intercept	- 1.60			
I try not to think about my allergy	0.33**	1.17	1.39	1.64
Knowledge about allergy	0.25**	1.16	1.29	1.42
<i>Never versus sometimes</i>				
Intercept	- 3.19			
Knowledge about allergy	0.35**	1.26	1.42	1.60
<i>Never versus often</i>				
Intercept	- 1.74			
Knowledge about allergy	0.75**	1.51	2.11	2.95
Loss of productivity	0.65*	1.37	1.91	2.66
I live like I do not have hay fever	- 2.96**	0.01	0.05	0.27
My mood is negatively affected by my symptoms	- 2.15**	0.03	0.12	0.52
[I live my life like I do not have a hay fever] × [My mood is negatively affected by my symptoms]	0.77**	1.37	2.16	3.42

\*Significance level  $p < 0.05$ , \*\*significance level  $p < 0.01$

$R^2 = 0.23$  (Cox and Snell). Model  $\chi^2$  (18) 174.96,  $p < 0.01$

533 the highest proportion of the participants had a high  
534 school diploma and were relatively young, mainly  
535 comprising students. Consequently, there is a certain  
536 extent of bias in the respondents' answers in this  
537 survey, as the study population represents a convenience  
538 sample. However, given the sample size and the  
539 significance levels in most of the findings, we do  
540 not expect that this "bias" altered the results significantly  
541 whatsoever. Moreover, our study's average age  
542 group (young students) exhibits the highest prevalence  
543 of allergic sensitization compared to other age groups  
544 (Blomme et al. 2013). Furthermore, there has been  
545 evidence that patients with high level of education  
546 tend to be more adherent (Ocak et al. 2017). We  
547 preferred not to collect any information on the specific  
548 symptoms of the allergic subjects, i.e., allergic  
549 bronchial asthma, allergic rhinitis and allergic conjunctivitis,  
550 as this would complicate the definition and characterization  
551 of symptomatology. We therefore preferred to keep the  
552 questionnaires as simple as possible so as to ensure high  
553 comprehension rate by the participants.  
554

In our study, the mean reported disease duration of  
collective questioned was 12.7 years, which sits below  
the value found by Petersen et al. (2008), namely  
17.4 years. This can be partly attributed to the average  
younger age of our study population, as our cohort was  
on average aged 26.8 years, in contrast to 33.6 years  
of that of Petersen et al. (2008). In comparison with the  
survey of Lombardi et al. (2015) with 39% of non-confirmed  
diagnoses, the proportion of not attested pollen allergies  
in the present sample is even small (17.4%) and might  
be attributed to the specific characteristics of the sample  
collected.

Symptoms of allergic disorders were found to be  
troublesome for the majority of allergic persons and to  
impair several dimensions of everyday life. Meltzer  
et al. (2017) reported a similar result in their survey of  
AR sufferers in the USA, where more than 50% of the  
respondents indicated impairment of daily activities  
and increased level of fatigue. The survey of Tanner  
et al. (1999) documented insights, which are even  
closer to that of our study: 96% of allergic subjects  
reporting impairment in daily activities, 93% in  
classroom productivity and 91% observed fall of

workplace productivity. In our study in Augsburg, a significant loss of productivity was found in 92.3% of questioned pollen allergic subjects. Allergy sufferers declared to be symptomatic for 9 weeks inside the pollen season and to experience a productivity loss of about 2.4 scores on a 10-step scale. This score would correspond to a 24% productivity reduction rate, considering a typical 8-h workday, which accounts for 1.9 lost work hours. Similar results have been reported also by Tanner et al. (1999), who documented 96% of allergic subjects declaring impairment in daily activities, 93% in classroom productivity and 91% observed fall of workplace productivity. Likewise, Lamb et al. (2006) found that employees suffering from allergic rhinitis had allergic symptoms for 52.5 days per year coming up for nearly 7.5 weeks and were unproductive for 2.3 h per typical 8-h workday, while they were symptomatic.

A unique feature of our study is that the human cohort questioned consisted mainly of students. Therefore, immediately a question is raised regarding relevant implications of reduced class/workplace productivity of this specific population group. Bensus (2016) documented that students with allergies might suffer a temporary reduction in cognitive abilities if exposed to pollen. It was found that high-education students, even after a short-interval of allergen exposure, can have long-run implications in terms of failing exams or of poor performance in classroom. Marcotte (2015) investigated the impact of pollen exposure on achievements in schools and found a robust correlation between increased pollen concentrations and reduced ability to perform on state assessments. This impact might be attributed to reduced cognitive abilities during the high-allergy-symptom period. Likewise, Trikojat et al. (2017) reported poorer performance of allergic patients in word list-based learning and a general slowing in information processing speed while being symptomatic. Moreover, according to Devillier et al. (2016a), work/classroom impairment seems to correlate strongly with perceived health-related quality of life, which tends to be lower in allergic persons while being symptomatic.

The present study provided evidence that the female subjects were significantly more burdened by hay fever symptoms in terms of loss of productivity, limitations in both, daily routines and social life, although the perceived allergy severity does not significantly differ. In the survey of Kalpaklioglu

and Baççioğlu (2008), female gender was found to be a determinant of impaired quality of life in subjects with allergic rhinitis or asthma in all measures of the health-related quality of life, except for social functioning. Also in the study of Valls-Mateus et al. (2017), female subjects suffering from nasal obstructive disorders reported statistically lower health-related quality of life compared to men. Bedolla-Barajas et al. (2017) have reported that allergic rhinitis is associated with anxiety and depression in women.

From the viewpoint of the health sciences, there are no straightforward reasons that can be responsible for poorer health-related quality of life in women suffering from the same illness of the same severity. Therefore, it is worth investigating other reasons, for instance personality. First of all, self-reported allergy prevalence has been found to be considerably higher in females than in males (Atzpodien and Lampert 2009; Langen et al. 2013), although it remains controversial whether this discrepancy does exist. The possible reason for this tendency could lie in the higher awareness of allergy among women, or in the fact that women generally take care their health more. The GEDA-survey in 2012 showed that the females of the same age group estimate their health to be worse than that of men, and, furthermore, revealed that significantly more women than men referred to themselves as psychologically burdened (Lange 2014). Although self-evaluation does not always correspond to an objective state of health, it determines the participation in social life. If women perceive themselves as more burdened, they might feel more limited in everyday life. Moreover, mental health, together with physical health, is crucial for individual quality of life. Some interesting insights have been provided by Axelsson et al. (2014), who managed to partly explain the gender-specific discrepancy. Among others, they investigated the relationship between personality and health-related quality of life. They have shown that neuroticism is negatively related to mental quality of life and negatively correlated with physical health-related quality of life. Due to descriptive results of the survey, women scored significantly higher on neuroticism than men did (Axelsson et al. 2014).

The present survey showed that a considerably large share of allergic subjects do not treat their allergy properly and prefer to self-manage their disease. The most common reason for this tendency is low symptom severity. Nearly 74% of respondents claimed to

676 take allergic medication to relieve their symptoms and  
 677 most of them preferred oral antihistamines, as has  
 678 been shown also by other scientists (Demoly et al.  
 679 2002; Lombardi et al. 2015; Schramm et al. 2003). As  
 680 the biggest part of the pollen allergy sufferers was  
 681 treating their disease when symptomatic with over-  
 682 the-counter medication, this made likely to show  
 683 relatively low treatment satisfaction, as reported  
 684 before by Meltzer et al. (2017). Likewise, Horn et al.  
 685 (2016) have documented that unspecific symptomatic  
 686 medication actually provides no improvement in the  
 687 perceived health-related quality of life in allergic  
 688 patients. The utilization rate of specific immunother-  
 689 apy remained as low as 35.0% of our total cohort size,  
 690 a percentage similar to that of previous researches  
 691 (i.e., 31.7% by Weberschock et al. 2014).

692 The present study has shown that adequate treat-  
 693 ment of allergy is rare so it is important to look for the  
 694 reasons responsible for this tendency. The first evident  
 695 reason has been highlighted: those allergic subjects  
 696 who develop only weak symptoms do not consider  
 697 their illness as a serious health problem and are not  
 698 willing to make necessary effort for the treatment.  
 699 This insight was verified by the correlation between  
 700 increased symptom severity and the consequent deci-  
 701 sion to treat allergy and to undergo specific  
 702 immunotherapy. The cause for untreated or inade-  
 703 quately treated hay fever can lie in the lack of  
 704 information about the etiology and nature of allergic  
 705 diseases, as also proven by the significant relationship  
 706 between increased knowledge state and increased  
 707 probability of seeking medical attention and undergo-  
 708 ing specific immunotherapy. The study population  
 709 stated their level of knowledge to be relative low. In  
 710 view of the survey of Marple et al. (2007), an even  
 711 lower level of knowledge can be assumed. According  
 712 to its results, the majority of respondents (94%)  
 713 considered themselves at least somewhat knowledge-  
 714 able about seasonal allergies; however, their responses  
 715 about the nature of their condition and its treatment  
 716 suggested otherwise (Marple et al. 2007). Besides this,  
 717 the majority of the study population stated to be  
 718 looking for additional information about hay fever and  
 719 seeking advises about self-management of allergic  
 720 diseases.

721 Based on these findings, one of the most important  
 722 aspects in the improvement of allergy management is  
 723 patient empowerment through education. Patients  
 724 should be educated about their health condition,

725 different treatment options of their disease and the  
 726 correct use of pharmacotherapy, as well as be educated  
 727 to achieve allergen avoidance and prophylaxis.  
 728 Adherence to the treatment is another crucial aspect  
 729 of successful allergy treatment. In our cohort, an  
 730 approximate 40% of all allergic patients were taking  
 731 oral antihistamines on a daily basis. Those who were  
 732 not taking their illness seriously and were seeking  
 733 medical support, were also most likely not fully  
 734 satisfied with the current treatment, especially when  
 735 also considering the fact that doctors tend to rate  
 736 allergy as less severe than patients do (Marple et al.  
 737 2007). Hence, the patient–doctor relationship and  
 738 close communication are of crucial importance and the  
 739 allergic patient’s personality and gender ought to be  
 740 also taken into account when planning allergy  
 741 management.

## 6 Conclusion 742

743 The current research is an excellent paradigm of how  
 744 pollen allergies may have a profound health effect on  
 745 allergic individuals and clearly highlights that allergic  
 746 symptomatology can be exacerbated not only by the  
 747 disease per se, but also because the disease has not  
 748 been taken seriously by the patient. The latter seems to  
 749 be the result of multiple, interacting and complex  
 750 social and environmental factors. Selection of and  
 751 adherence to the most appropriate treatment and  
 752 consistent consultation of medical experts are some  
 753 of the typical health behavior characteristics that need  
 754 to be adopted by the allergic patient so as to maximize  
 755 the effectiveness of allergy management.

756 A holistic approach toward personalized medicine  
 757 is recommended to more effectively confront pollen  
 758 allergies. A prerequisite for this is to integrate factors  
 759 like personality traits, psychological factors and self-  
 760 perception level, which would ultimately involve  
 761 proper education and empowerment of allergic  
 762 individuals.

763 **Availability of data and material** The datasets  
 764 used/analyzed during the current study will be available upon  
 765 request.

766 **Compliance with ethical standards**

767 **Conflict of interest** The authors declare that they have no  
 768 conflict of interest.

769 **Informed consent** Informed consent was obtained from all  
770 individual participants included in the study.

771 **Human and animal rights statement** All procedures per-  
772 formed in studies involving human participants were in accord-  
773 ance with the ethical standards of the institutional and/or  
774 national research committee and with the 1964 Declaration of  
775 Helsinki and its later amendments or comparable ethical  
776 <sup>AQ3</sup> standards.

777 **Ethical approval** No clinical study was conducted, or  
778 biosamples have been used in this survey. All used personal data  
779 were ensured to remain anonymized. The University of Augs-  
780 burg has accepted the lack of need for such ethical approval.

## 781 References

782 Asher, I., & Pearce, N. (2014). Global burden of asthma among  
783 children. *The International Journal of Tuberculosis and*  
784 *Lung Disease: The Official Journal of the International*  
785 *Union Against Tuberculosis and Lung Disease*. <https://doi.org/10.5588/ijtld.14.0170>.

787 Atzpodien, K., & Lampert, T. (Eds.). (2009). *20 Jahre nach dem*  
788 *Fall der Mauer: Wie hat sich die Gesundheit in Deutsch-*  
789 *land entwickelt? (Beiträge zur Gesundheitsberichterstat-*  
790 *tung des Bundes)*. Berlin: Robert-Koch-Institute.

791 Axelsson, M., Brink, E., & Lotvall, J. (2014). A personality and  
792 gender perspective on adherence and health-related quality  
793 of life in people with asthma and/or allergic rhinitis.  
794 *Journal of the American Association of Nurse Practition-*  
795 *ers*. <https://doi.org/10.1002/2327-6924.12069>.

796 Badura, B., Hehlmann, T., & Walter, U. (2010). *Betriebliche*  
797 *Gesundheitspolitik: Der Weg zur gesunden Organisation*.  
798 Berlin: Springer.

799 Bedolla-Barajas, M., Morales-Romero, J., Pulido-Guillén, N.  
800 A., Robles-Figueroa, M., & Plascencia-Domínguez, B. R.  
801 (2017). Rhinitis as an associated factor for anxiety and  
802 depression amongst adults. *Brazilian Journal of Otorhi-*  
803 *nolaryngology*. <https://doi.org/10.1016/j.bjorl.2016.05.008>.

805 Bender, B. G. (2015). Motivating patient adherence to allergic  
806 rhinitis treatments. *Current Allergy and Asthma Reports*.  
807 <https://doi.org/10.1007/s11882-014-0507-8>.

808 Bensus, S. S. (2016). You sneeze, you lose: The impact of  
809 pollen exposure on cognitive performance during high-  
810 stakes high school exams. *Journal of Health Economics*.  
811 <https://doi.org/10.1016/j.jhealeco.2016.05.005>.

812 Blaiss, M. S. (2007). Allergic rhinoconjunctivitis: Burden of  
813 disease. *Allergy and Asthma Proceedings: The Official*  
814 *Journal of Regional and State Allergy Societies*. <https://doi.org/10.2500/aap.2007.28.3013>.

815 Blaiss, M. S., Hammerby, E., Robinson, S., Kennedy-Martin, T.,  
816 & Buchs, S. (2018). The burden of allergic rhinitis and  
817 allergic rhinoconjunctivitis on adolescents: A literature  
818 review. *Annals of Allergy, Asthma & Immunology: Official*  
819 *Publication of the American College of Allergy, Asthma, &*  
820 *Immunology*. <https://doi.org/10.1016/j.anai.2018.03.028>.

822 Blomme, K., Tomassen, P., Lapeere, H., Huvenne, W., Bonny,  
823 M., Acke, F., et al. (2013). Prevalence of allergic

sensitization versus allergic rhinitis symptoms in an unse-  
lected population. *International Archives of Allergy and*  
*Immunology*, 1, 1. <https://doi.org/10.1159/000339853>.  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884

Carroll, C. L., Balkrishnan, R., Feldman, S. R., Fleischer, A. B.,  
& Manuel, J. C. (2005). The burden of atopic dermatitis:  
Impact on the patient, family, and society. *Pediatric Der-*  
*matology*. <https://doi.org/10.1111/j.1525-1470.2005.22303.x>.

Demoly, P., Allaert, F.-A., & Lecasble, M. (2002). ERASM, a  
pharmacoepidemiologic survey on management of inter-  
mittent allergic rhinitis in everyday general medical prac-  
tice in France. *Allergy*. <https://doi.org/10.1034/j.1398-9995.2002.t01-1-13370.x>.

Devillier, P., Bousquet, P.-J., Grassin-Delyle, S., Salvator, H.,  
Demoly, P., Bousquet, J., et al. (2016a). Comparison of  
outcome measures in allergic rhinitis in children, adoles-  
cents and adults. *Pediatric Allergy and Immunology: Official*  
*Publication of the European Society of Pediatric*  
*Allergy and Immunology*. <https://doi.org/10.1111/pai.12561>.

Devillier, P., Bousquet, J., Salvator, H., Naline, E., Grassin-  
Delyle, S., & de Beaumont, O. (2016b). In allergic rhinitis,  
work, classroom and activity impairments are weakly  
related to other outcome measures. *Clinical and Experimen-*  
*tal Allergy: Journal of the British Society for Allergy*  
*and Clinical Immunology*. <https://doi.org/10.1111/cea.12801>.

Goetzel, R. Z., Long, S. R., Ozminkowski, R. J., Hawkins, K.,  
Wang, S., & Lynch, W. (2004). Health, absence, disability,  
and presenteeism cost estimates of certain physical and  
mental health conditions affecting U.S. employers. *Journal*  
*of Occupational and Environmental Medicine*. <https://doi.org/10.1097/01.jom.0000121151.40413.bd>.

Haanpää, L., Af Ursin, P., Nermes, M., Kaljonen, A., & Isolauri,  
E. (2018). Association of allergic diseases with children's  
life satisfaction: Population-based study in Finland. *British*  
*Medical Journal Open*. <https://doi.org/10.1136/bmjopen-2017-019281>.

Horn, A., Zeuner, H., Wolf, H., Schnitker, J., & Wüstenberg, E.  
(2016). Health-related quality of life during routine treat-  
ment with the SQ-standardised grass allergy immunother-  
apy tablet: A non-interventional observational study. *Clinical*  
*Drug Investigation*. <https://doi.org/10.1007/s40261-016-0388-9>.

Jáuregui, I., Mullol, J., Dávila, I., Ferrer, M., Bartra, J., del  
Cuvillo, A., et al. (2009). Allergic rhinitis and school  
performance. *Journal of Investigational Allergology and*  
*Clinical Immunology*, 19(Suppl 1), 32–39.

Jernelöv, S., Lekander, M., Almqvist, C., Axelsson, J., &  
Larsson, H. (2013). Development of atopic disease and  
disturbed sleep in childhood and adolescence—A longi-  
tudinal population-based study. *Clinical and Experimental*  
*Allergy: Journal of the British Society for Allergy and*  
*Clinical Immunology*, 1, 1. <https://doi.org/10.1111/cea.12087>.

Kalpaklıoğlu, A. F., & Baççioğlu, A. (2008). Evaluation of  
quality of life: Impact of allergic rhinitis on asthma. *Journal*  
*of Investigational Allergology and Clinical*  
*Immunology*, 18(3), 168–173.

Klossek, J. M., Annesi-Maesano, I., Pribil, C., & Didier, A.  
(2012). The burden associated with ocular symptoms in



- 885 allergic rhinitis. *International Archives of Allergy and Immunology*. <https://doi.org/10.1159/000334286>.
- 886 Lamb, C. E., Ratner, P. H., Johnson, C. E., Ambegaonkar, A. J.,
- 887 Joshi, A. V., Day, D., et al. (2006). Economic impact of
- 888 workplace productivity losses due to allergic rhinitis
- 889 compared with select medical conditions in the United
- 890 States from an employer perspective. *Current Medical*
- 891 *Research and Opinion*. [https://doi.org/10.1185/](https://doi.org/10.1185/030079906X112552)
- 892 [030079906X112552](https://doi.org/10.1185/030079906X112552).
- 893 Lange, C. (2014). *Daten und Fakten: Ergebnisse der Studie*
- 894 *“Gesundheit in Deutschland aktuell 2012” (Beiträge zur*
- 895 *Gesundheitsberichterstattung des Bundes)*. Berlin: Robert-
- 896 Koch-Institute.
- 897 Langen, U., Schmitz, R., & Steppuhn, H. (2013). Häufigkeit
- 898 allergischer Erkrankungen in Deutschland: Ergebnisse der
- 899 Studie zur Gesundheit Erwachsener in Deutschland
- 900 (DEGS1). *Bundesgesundheitsblatt, Gesundheitsforschung,*
- 901 *Gesundheitsschutz*. [https://doi.org/10.1007/s00103-012-](https://doi.org/10.1007/s00103-012-1652-7)
- 902 [1652-7](https://doi.org/10.1007/s00103-012-1652-7).
- 903 Leynaert, B., Neukirch, C., Liard, R., Bousquet, J., & Neukirch,
- 904 F. (2000). Quality of life in allergic rhinitis and asthma. A
- 905 population-based study of young adults. *American Journal*
- 906 *of Respiratory and Critical Care Medicine*. [https://doi.org/](https://doi.org/10.1164/ajrccm.162.4.9912033)
- 907 [10.1164/ajrccm.162.4.9912033](https://doi.org/10.1164/ajrccm.162.4.9912033).
- 908 Linneberg, A., Dam Petersen, K., Hahn-Pedersen, J., Ham-
- 909 merby, E., Serup-Hansen, N., & Boxall, N. (2016). Burden
- 910 of allergic respiratory disease: A systematic review. *Clinical*
- 911 *and Molecular Allergy: CMA*. [https://doi.org/10.1186/](https://doi.org/10.1186/s12948-016-0049-9)
- 912 [s12948-016-0049-9](https://doi.org/10.1186/s12948-016-0049-9).
- 913 Lombardi, C., Musicco, E., Rastrelli, F., Bettoncelli, G., Pas-
- 914 salacqua, G., & Canonica, G. W. (2015). The patient with
- 915 rhinitis in the pharmacy. A cross-sectional study in real life.
- 916 *Asthma Research and Practice*. [https://doi.org/10.1186/](https://doi.org/10.1186/s40733-015-0002-6)
- 917 [s40733-015-0002-6](https://doi.org/10.1186/s40733-015-0002-6).
- 918 Marcotte, D. E. (2015). Allergy test: Seasonal allergens and
- 919 performance in school. *Journal of Health Economics*. <https://doi.org/10.1016/j.jhealeco.2015.01.002>.
- 920 Marple, B. F., Fornadley, J. A., Patel, A. A., Fineman, S. M.,
- 921 Fromer, L., Krouse, J. H., et al. (2007). Keys to successful
- 922 management of patients with allergic rhinitis: Focus on
- 923 patient confidence, compliance, and satisfaction. *Otolaryngology—Head and Neck Surgery: Official Journal of*
- 924 *American Academy of Otolaryngology—Head and Neck*
- 925 *Surgery*. <https://doi.org/10.1016/j.otohns.2007.02.031>.
- 926 May, J. R., & Dolen, W. K. (2017). Management of allergic
- 927 rhinitis: A review for the community pharmacist. *Clinical*
- 928 *Therapeutics*. [https://doi.org/10.1016/j.clinthera.2017.10.](https://doi.org/10.1016/j.clinthera.2017.10.006)
- 929 [006](https://doi.org/10.1016/j.clinthera.2017.10.006).
- 930 Meadows, A., Kaambwa, B., Novielli, N., Huissoon, A., Fry-
- 931 Smith, A., Meads, C., et al. (2013). A systematic review
- 932 and economic evaluation of subcutaneous and sublingual
- 933 allergen immunotherapy in adults and children with sea-
- 934 sonal allergic rhinitis. *Health Technology Assessment*
- 935 *(Winchester, England)*. <https://doi.org/10.3310/hta17270>.
- 936 Meltzer, E. O. (2001). Quality of life in adults and children with
- 937 allergic rhinitis. *Journal of Allergy and Clinical*
- 938 *Immunology*. <https://doi.org/10.1067/mai.2001.115566>.
- 939 Meltzer, E. O. (2016). Allergic rhinitis: Burden of illness,
- 940 quality of life, comorbidities, and control. *Immunology and*
- 941 *Allergy Clinics of North America*. [https://doi.org/10.1016/](https://doi.org/10.1016/j.iac.2015.12.002)
- 942 [j.iac.2015.12.002](https://doi.org/10.1016/j.iac.2015.12.002).
- 943 Meltzer, E. O., Farrar, J. R., & Sennett, C. (2017). Findings from
- 944 an online survey assessing the burden and management of
- 945 seasonal allergic rhinoconjunctivitis in US patients. *The*
- 946 *Journal of Allergy and Clinical Immunology. In Practice*. <https://doi.org/10.1016/j.jaip.2016.10.010>.
- 947 Muñoz-Cano, R., Ribó, P., Araujo, G., Giralt, E., Sanchez-
- 948 Lopez, J., & Valero, A. (2018). Severity of allergic rhinitis
- 949 impacts sleep and anxiety: Results from a large Spanish
- 950 cohort. *Clinical and Translational Allergy*. [https://doi.org/](https://doi.org/10.1186/s13601-018-0212-0)
- 951 [10.1186/s13601-018-0212-0](https://doi.org/10.1186/s13601-018-0212-0).
- 952 Ocak, E., Acar, B., & Kocaöz, D. (2017). Medical adherence to
- 953 intranasal corticosteroids in adult patients. *Brazilian*
- 954 *Journal of Otorhinolaryngology*. [https://doi.org/10.1016/j.](https://doi.org/10.1016/j.bjorl.2016.06.007)
- 955 [bjorl.2016.06.007](https://doi.org/10.1016/j.bjorl.2016.06.007).
- 956 Passali, D., Cingi, C., Staffa, P., Passali, F., Muluk, N. B., &
- 957 Bellussi, M. L. (2018). The international study of the
- 958 allergic rhinitis survey: Outcomes from 4 geographical
- 959 regions. *Asia Pacific Allergy*. [https://doi.org/10.5415/](https://doi.org/10.5415/apallergy.2018.8.e7)
- 960 [apallergy.2018.8.e7](https://doi.org/10.5415/apallergy.2018.8.e7).
- 961 Petersen, K. D., Kronborg, C., Gyrd-Hansen, D., Dahl, R.,
- 962 Larsen, J. N., & Løwenstein, H. (2008). Quality of life in
- 963 rhinoconjunctivitis assessed with generic and disease-
- 964 specific questionnaires. *Allergy*. [https://doi.org/10.1111/j.](https://doi.org/10.1111/j.1398-9995.2007.01583.x)
- 965 [1398-9995.2007.01583.x](https://doi.org/10.1111/j.1398-9995.2007.01583.x).
- 966 Ring, J., Akdis, C., Behrendt, H., Lauener, R. P., Schäppi, G.,
- 967 Akdis, M., et al. (2012). Davos declaration: Allergy as a
- 968 global problem. *Allergy*. [https://doi.org/10.1111/j.1398-](https://doi.org/10.1111/j.1398-9995.2011.02770.x)
- 969 [9995.2011.02770.x](https://doi.org/10.1111/j.1398-9995.2011.02770.x).
- 970 Schoenwetter, W. F., Dupclay, L., Appajosyula, S., Botteman,
- 971 M. F., & Pashos, C. L. (2004). Economic impact and
- 972 quality-of-life burden of allergic rhinitis. *Current Medical*
- 973 *Research and Opinion*. [https://doi.org/10.1185/](https://doi.org/10.1185/030079903125003053)
- 974 [030079903125003053](https://doi.org/10.1185/030079903125003053).
- 975 Schramm, B., Ehlken, B., Smala, A., Quednau, K., Berger, K., &
- 976 Nowak, D. (2003). Cost of illness of atopic asthma and
- 977 seasonal allergic rhinitis in Germany: 1-yr retrospective
- 978 study. *European Respiratory Journal*. [https://doi.org/10.](https://doi.org/10.1183/09031936.03.00019502)
- 979 [1183/09031936.03.00019502](https://doi.org/10.1183/09031936.03.00019502).
- 980 Simpson, E. L., Bieber, T., Eckert, L., Wu, R., Ardeleanu, M.,
- 981 Graham, N. M. H., et al. (2016). Patient burden of moderate
- 982 to severe atopic dermatitis (AD): Insights from a phase 2b
- 983 clinical trial of dupilumab in adults. *Journal of the American*
- 984 *Academy of Dermatology*. [https://doi.org/10.1016/j.](https://doi.org/10.1016/j.jaad.2015.10.043)
- 985 [jaad.2015.10.043](https://doi.org/10.1016/j.jaad.2015.10.043).
- 986 Tan, R., Cvetkovski, B., Kritikos, V., Price, D., Yan, K., Smith,
- 987 P., et al. (2017). Identifying the hidden burden of allergic
- 988 rhinitis (AR) in community pharmacy: A global phenom-
- 989 enon. *Asthma Research and Practice*. <https://doi.org/10.1186/s40733-017-0036-z>.
- 990 Tanner, L. A., Reilley, M., Meltzer, E. O., Bradford, J., &
- 991 Mason, J. (1999). Effect of fexofenadine HCl on quality of
- 992 life and work, classroom, and daily activity impairment in
- 993 patients with seasonal allergic rhinitis. *The American*
- 994 *Journal of Managed Care*, 4(5), 235–247.
- 995 Traidl-Hoffmann, C. (2017). Allergie – eine Umwelt-
- 996 krankung! *Bundesgesundheitsblatt, Gesundheits-*
- 997 *forschung, Gesundheitsschutz*. [https://doi.org/10.1007/](https://doi.org/10.1007/s00103-017-2547-4)
- 998 [s00103-017-2547-4](https://doi.org/10.1007/s00103-017-2547-4).
- 999 Trikojot, K., Buske-Kirschbaum, A., Plessow, F., Schmitt, J., &
- 1000 Fischer, R. (2017). Memory and multitasking performance
- 1001 during acute allergic inflammation in seasonal allergic
- 1002
- 1003
- 1004
- 1005
- 1006

- 1007 rhinitis. *Clinical and Experimental Allergy: Journal of the*  
 1008 *British Society for Allergy and Clinical Immunology*.  
 1009 <https://doi.org/10.1111/cea.12893>.
- 1010 Valls-Mateus, M., Marino-Sanchez, F., Ruiz-Echevarría, K.,  
 1011 Cardenas-Escalante, P., Jiménez-Feijoo, R., Blasco-  
 1012 Lozano, J., et al. (2017). Nasal obstructive disorders impair  
 1013 health-related quality of life in adolescents with persistent  
 1014 allergic rhinitis: A real-life study. *Pediatric Allergy and*  
 1015 *Immunology: Official Publication of the European Society*  
 1016 *of Pediatric Allergy and Immunology*. <https://doi.org/10.1111/pai.12724>.
- 1017  
 1018 Vandenplas, O., Vinnikov, D., Blanc, P. D., Agache, I., Bachert,  
 1019 C., Bewick, M., et al. (2018). Impact of rhinitis on work  
 1020 productivity: A systematic review. *The Journal of Allergy*  
 1021 *and Clinical Immunology: In Practice*. <https://doi.org/10.1016/j.jaip.2017.09.002>.
- 1022  
 1023 Vuurman, E. F. P. M., Vuurman, L. L., Lutgens, I., & Kremer, B.  
 1024 (2014). Allergic rhinitis is a risk factor for traffic safety.  
 1025 *Allergy*. <https://doi.org/10.1111/all.12418>.
- 1026 Weberschock, T., Schaefer, I., Heigel, H., Valesky, E., Augustin,  
 1027 M., & Schmitt, J. (2014). Use of specific  
 1028 immunotherapy—A survey of 15 164 employed persons in  
 1029 Germany. *Journal der Deutschen Dermatologischen*  
 1030 *Gesellschaft = Journal of the German Society of Derma-*  
 1031 *tology: JDDG*. <https://doi.org/10.1111/ddg.12298>.
- 1032 Zuberbier, T., Lötval, J., Simoens, S., Subramanian, S. V., &  
 1033 Church, M. K. (2014). Economic burden of inadequate  
 1034 management of allergic diseases in the European Union: A  
 1035 GA(2) LEN review. *Allergy*. <https://doi.org/10.1111/all.12470>.  
 1036

UNCORRECTED PROOF

Journal : **10453**

Article : **9563**

## Author Query Form

**Please ensure you fill out your response to the queries raised below and return this form along with your corrections**

Dear Author

During the process of typesetting your article, the following queries have arisen. Please check your typeset proof carefully against the queries listed below and mark the necessary changes either directly on the proof/online grid or in the 'Author's response' area provided below

Query	Details Required	Author's Response
AQ1	Kindly check and confirm whether the corresponding author is correctly identified and amend if necessary.	
AQ2	Please confirm the section headings are correctly identified.	
AQ3	Kindly note that the heading "Human and animal rights statement" is inserted. Amend if necessary.	